Management of Oliguria
Assessment and Initial Management
- For a patient with oliguria, the first step should be to assess volume status and implement judicious protocol-driven volume resuscitation while avoiding potentially nephrotoxic medications or procedures, as recommended by the American College of Physicians 1
- The current urine output of 40 ml/hr for 2 hours meets criteria for oliguria, but has not persisted long enough to meet formal AKI criteria, according to the American Journal of Kidney Diseases 2, 1
- Oliguria must persist for at least 6 hours to qualify as AKI, based on KDIGO criteria 3
- The American College of Physicians recommends assessing volume status and providing fluid resuscitation if indicated, with a target of a positive fluid response, including a ≥10% increase in blood pressure, ≥10% reduction in heart rate, and/or improvement in mental status, peripheral perfusion, or urine output 1, 4
Medication Management
- The American College of Physicians recommends discontinuing potential nephrotoxic medications, reviewing all medications and stopping those with known nephrotoxic effects, and adjusting medication doses based on estimated kidney function 2, 1, 5
Hemodynamic Optimization
- The American College of Physicians recommends ensuring mean arterial pressure ≥60 mmHg, considering vasopressors if fluid resuscitation fails to maintain adequate blood pressure, and using norepinephrine as the vasopressor of choice if needed 5
Further Evaluation and Management
- The American College of Physicians recommends obtaining serum creatinine to assess for AKI, and considering the pattern of oliguria, including transient oliguria and oliguria accompanied by hemodynamic compromise or increasing vasopressor requirements 2, 6
- The American College of Physicians recommends assessing for specific causes of oliguria, including pre-renal, renal, and post-renal causes 4, 3, 2
- The American College of Physicians recommends avoiding using oliguria alone as a surrogate endpoint for clinical decisions, and considering novel biomarkers to distinguish between kidney damage and functional changes 1